Figure 1. The proportion of patients who achieved ACR20 in FINCH 4 according to the parent study: FINCH 1 (A), FINCH 2 (B) and FINCH 3 (C) (safety analysis set, NRI). Patients with missing outcomes were set as non-responders. ACR20 was calculated based on the parent study baseline. Error bars show 95% CIs. ACR20, American College of Rheumatology 20% response; FIL(100/200), filgotinib (100 mg/200 mg); NRI, non-responder imputation.